Hbm Holdings Ltd

HBM Holdings Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of antibody therapeutics for immunology and oncology. It operates in Mainland China, the United States, Europe, and internationally. The company develops the Harbour Mice Platform, which generates human monoclonal antibodies in H2L2 and heavy-chain formats. Its pipeline includes Batoclimab (HBM9161) for myasthenia gravis, Porustobart (HBM4003) for melanoma, colorectal cancer, hepatocellular carcinoma, and neuroendocrine neoplasm, as well as HBM7020 for hepatocellular carcinoma and autoimmune diseases, HBM9378 for asthma and chronic obstructive pulmonary disease, and HBM1020, HBM7022, HBM7008, HBM9027, HBM7004, and HBM9033 for solid tumors. The company has a strategic collaboration with Evinova to apply AI and digital technologies to enhance biologics development efficiency. Incorporated in 2016, HBM Holdings is based in Suzhou, the People's Republic of China.